Skip to content
Screener

BioMarin Pharmaceuticals BMRN Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$76.25M-50.8%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$218.28M+69.0%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
——

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
ASSETSJune 30, 2026 / (unaudited)December 31, 2025 ⁽¹⁾
Current assets:
Cash and cash equivalents$874,005$1,311,679
Short-term investments—248,930
Accounts receivable, net1,061,047908,214
Inventory1,782,5241,298,883
Other current assets254,047185,784
Total current assets3,971,6233,953,490
Noncurrent assets:

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's available for sale securities debt securities current?
BioMarin Pharmaceuticals (BMRN) reported available for sale securities debt securities current of $0 in Q2 2026.
How has BioMarin Pharmaceuticals's available for sale securities debt securities current changed year-over-year?
BioMarin Pharmaceuticals's available for sale securities debt securities current decreased by 100.0% year-over-year, from $218.31M to $0.
What is the long-term trend for BioMarin Pharmaceuticals's available for sale securities debt securities current?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's available for sale securities debt securities current has grown at a -9.8% compound annual growth rate (CAGR), from $416.23M to $248.93M.
What does available for sale securities debt securities current mean?
Available For Sale Securities Debt Securities Current

Ask your AI about BioMarin Pharmaceuticals's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude